

NEW APAS®-AMR DATA PRESENTED AT GLOBAL CONFERENCE

APAS® Independence showcased on Thermo Fisher Scientific Booth

Adelaide, Australia, 19 April 2023: Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT or the Company**), a leader in medical technology automation using artificial intelligence, is pleased to announce the Company's APAS® technology was presented at the annual European Congress of Clinical Microbiology and Infectious Diseases (**ECCMID**) conference held in Copenhagen, Denmark (15 – 18 April 2023).

Key Points:

- **ECCMID 2023: Global conference for clinical microbiology held in Copenhagen, Denmark (15 – 18 April 2023)**
- **APAS® Independence showcased on Thermo Fisher Scientific booth for European product launch**
- **Two publications featuring new APAS®-AMR clinical data presented at the conference**
- **Key Opinion Leaders from Germany and UK share their experiences using APAS® technology**

The annual ECCMID conference is one of the most comprehensive and influential conferences, held each year, in the field of infectious diseases and clinical microbiology. With attendees from around the world, the conference provides an excellent opportunity to showcase the latest technology advances and innovations. At this year's conference, the APAS® Independence was presented to delegates by Thermo Fisher Scientific, Inc (**Thermo Fisher**), with the instrument displayed on their booth as the Exclusive Distributor for the APAS® Independence in Europe and the United States.

During the conference, a dedicated launch event for the APAS® Independence was held by Thermo Fisher (*video highlight: <https://www.linkedin.com/feed/update/urn:li:activity:7053644832283512832/>*). The event included talks from Dr Hilmar Wisplinghoff (Labor Dr Wisplinghoff, Germany) and Alan Williams (Health Services Laboratory, UK) who shared their experiences using the APAS® technology. Delegates were also encouraged to see the APAS® instrument in action to gain hand-on experience with the technology.



LBT CEO and Managing

Director, Mr Brent Barnes said:

“This year’s ECCMID conference was the first following the appointment of Thermo Fisher as exclusive distributor in Europe. It was fantastic to see our APAS® technology launched under their brand and the engagement with customers by the Thermo Fisher sales team. Even better was seeing a number of our customers advocating to delegates about the real benefits they experience from the technology, which provides the ultimate validation of APAS®.”

New clinical data featuring APAS®-AMR

This year’s conference had a strong focus on antimicrobial resistance (**AMR**), which featured as a priority area within the scientific program. There were two poster publications presented featuring the Company’s APAS®-AMR technology for automated antimicrobial susceptibility testing. The publications presented new clinical data from Labor Dr Wisplinghoff, Germany and St Vincent’s Hospital, Melbourne demonstrating both the accuracy of the technology and potential to deliver workflow improvements for laboratories. Independent clinical data, such as these posters, is critical to build awareness of the technology and establish trust with potential customers.

LBT Scientific Director, Dr Steven Giglio said:

“The data presented this year at ECCMID is reimagining how technologies can be used to help tackle antimicrobial resistance. The data from Labor Wisplinghoff demonstrates the agility of APAS®-AMR to respond rapidly to new antimicrobial tests not available on any other commercial system. The data from St. Vincent’s is challenging the normal modality of testing and demonstrates the opportunity of APAS®-AMR to deliver improved turnaround times which directly impacts patient care. It is immensely satisfying to see the technology stretched to provide value to laboratories and patients.”

Approved for release by the Chair of the LBT Board.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of culture plate specimen processing. The Company’s second product, the Automated Plate Assessment System (APAS® Independence) uses LBT’s intelligent imaging and machine learning software to automate the imaging, analysis and interpretation of culture plates following incubation. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT’s wholly owned subsidiary Clever Culture Systems AG (CCS). Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

LBT Innovations
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com